Is there a certain type of myeloma patient who would be more likely to develop amyloidosis?

Is there a certain type of myeloma patient who would be more likely to develop amyloidosis?
What are some promising investigational agents and novel therapies for relapsed/refractory patients?
Are there any targeted approaches for specific genetic subsets that patients should ask about?
Is there a role for conventional chemotherapy in the treatment of relapsed and refractory myeloma?
What are the two approaches to treating smoldering myeloma?
How and why should I obtain a second opinion?
What is IgM MGUS?
How long does it take to see a response to anti-myeloma therapy?